uniQure N.V. Share-based Payment Arrangement, Expense
uniQure N.V. (QURE) reported Share-based Payment Arrangement, Expense of $22.26 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2025-02-27
- uniQure N.V. share-based payment arrangement, expense for the quarter ending 2018-12-31 was $3.34M, a 22.32% decline year-over-year.
- uniQure N.V. share-based payment arrangement, expense for the quarter ending 2018-09-30 was $2.62M, a 7.03% increase year-over-year.
- uniQure N.V. share-based payment arrangement, expense for the quarter ending 2018-06-30 was $2.21M, a 14.49% increase year-over-year.
- uniQure N.V. share-based payment arrangement, expense for the quarter ending 2018-03-31 was $2.53M, a 57.45% increase year-over-year.
- uniQure N.V. share-based payment arrangement, expense for fiscal 2024 was $22.26M, a 36.57% decline from fiscal 2023.
- uniQure N.V. share-based payment arrangement, expense for fiscal 2023 was $35.09M, a 2.60% increase from fiscal 2022.
- uniQure N.V. share-based payment arrangement, expense for fiscal 2022 was $34.20M, a 33.43% increase from fiscal 2021.
- uniQure N.V. share-based payment arrangement, expense for fiscal 2021 was $25.64M, a 17.42% increase from fiscal 2020.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $22.26M 10-K · filed 2025-02-27 | ||||
| 2023-12-31 | $35.09M 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | $34.20M 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $25.64M 10-K · filed 2024-02-28 | $25.61M 10-K · filed 2022-02-25 | |||
| 2020-12-31 | $21.83M 10-K · filed 2023-02-27 | $21.79M 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $17.47M 10-K · filed 2022-02-25 | ||||
| 2018-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $5.96M derived: sum of 2 quarters · filed 2021-03-01 | $8.17M derived: sum of 3 quarters · filed 2021-03-01 | $10.69M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $2.62M 10-Q · filed 2018-11-06 | $4.82M derived: sum of 2 quarters · filed 2018-11-06 | $7.35M 10-Q · filed 2018-11-06 | $11.65M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | $2.21M 10-Q · filed 2018-08-08 | $4.73M 10-Q · filed 2018-08-08 | $9.03M derived: sum of 3 quarters · filed 2020-03-02 | $11.48M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $2.53M 10-Q · filed 2018-04-30 | $6.83M derived: sum of 2 quarters · filed 2020-03-02 | $9.28M derived: sum of 3 quarters · filed 2020-03-02 | $11.20M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $6.75M derived: sum of 2 quarters · filed 2020-03-02 | $8.68M derived: sum of 3 quarters · filed 2020-03-02 | $10.28M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $2.45M 10-Q · filed 2018-11-06 | $4.37M derived: sum of 2 quarters · filed 2018-11-06 | $5.98M 10-Q · filed 2018-11-06 | $7.17M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $1.93M 10-Q · filed 2018-08-08 | $3.53M 10-Q · filed 2018-08-08 | $4.72M derived: sum of 3 quarters · filed 2019-02-28 | $5.65M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | $1.60M 10-Q · filed 2018-04-30 | $2.80M derived: sum of 2 quarters · filed 2019-02-28 | $3.72M derived: sum of 3 quarters · filed 2019-02-28 | $5.17M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $2.12M derived: sum of 2 quarters · filed 2019-02-28 | $3.57M derived: sum of 3 quarters · filed 2019-02-28 | $6.21M 10-K · filed 2019-02-28 | |
| 2016-09-30 | $923.00K 10-Q · filed 2017-11-01 | $2.37M derived: sum of 2 quarters · filed 2017-11-01 | $5.02M 10-Q · filed 2017-11-01 | ||
| 2016-06-30 | $1.45M 10-Q · filed 2017-08-08 | $4.10M 10-Q · filed 2017-08-08 | |||
| 2016-03-31 | $2.65M 10-Q · filed 2017-05-09 | ||||
| 2015-12-31 | $11.62M 10-K · filed 2018-03-14 | ||||
| 2014-12-31 | $8.40M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |